10/ 647,156

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1202txn

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JUL 02	LMEDLINE coverage updated
NEWS 3	JUL 02	SCISEARCH enhanced with complete author names
NEWS 4	JUL 02	CHEMCATS accession numbers revised
NEWS 5	JUL 02	CA/CAplus enhanced with utility model patents from China
NEWS 6	JUL 16	CAplus enhanced with French and German abstracts
NEWS 7	JUL 18	CA/CAplus patent coverage enhanced
NEWS 8	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS 9	JUL 30	USGENE now available on STN
NEWS 10	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS 11	AUG 06	FSTA enhanced with new thesaurus edition
NEWS 12	AUG 13	CA/CAplus enhanced with additional kind codes for granted patents
NEWS 13	AUG 20	CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS 14	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 15	AUG 27	USPATOLD now available on STN
NEWS 16	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 17	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 18	SEP 13	FORIS renamed to SOFIS
NEWS 19	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS 20	SEP 17	CA/CAplus enhanced with printed CA page images from 1967-1998
NEWS 21	SEP 17	CAplus coverage extended to include traditional medicine patents
NEWS 22	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 23	OCT 02	CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS 24	OCT 19	BEILSTEIN updated with new compounds

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific

10/ 647,156

research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 17:35:10 ON 01 NOV 2007

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 17:35:17 ON 01 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 31 OCT 2007 HIGHEST RN 952181-70-3
DICTIONARY FILE UPDATES: 31 OCT 2007 HIGHEST RN 952181-70-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10647156a.str

10/ 647,156





chain nodes :
7 8 9 10 12 28 29 30 35
ring nodes :
1 2 3 4 5 6 11 13 14 15 16 17 18 19 20 21 22 23
chain bonds :
2-35 5-7 7-8 8-9 9-10 10-11 10-12 28-29 29-30
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 11-13 11-17 13-14 14-15 15-16 16-17 18-19
18-23 19-20 20-21 21-22 22-23
exact/norm bonds :
2-35 8-9 9-10 10-12 29-30
exact bonds :
5-7 7-8 10-11 28-29
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 11-13 11-17 13-14 14-15 15-16 16-17 18-19
18-23 19-20 20-21 21-22 22-23
isolated ring systems :
containing 1 : 11 : 18 :

G1:N,Hy,[*1]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:Atom 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 28:CLASS 29:CLASS 30:CLASS 35:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS

10/ 647,156

L1 STR





G1 N,Hy,[@1]

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 17:36:07 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 10241 TO ITERATE

19.5% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 198755 TO 210885
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 ful
FULL SEARCH INITIATED 17:36:15 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 205713 TO ITERATE

100.0% PROCESSED 205713 ITERATIONS 22 ANSWERS
SEARCH TIME: 00.00.08

L3 22 SEA SSS FUL L1

=> file zcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	172.55	172.76

FILE 'ZCAPLUS' ENTERED AT 17:36:30 ON 01 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

10/ 647,156

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS is strictly prohibited.

FILE COVERS 1907 - 1 Nov 2007 VOL 147 ISS 19
FILE LAST UPDATED: 31 Oct 2007 (20071031/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s l3
L4          10 L3

=> d his

     (FILE 'HOME' ENTERED AT 17:35:10 ON 01 NOV 2007)

     FILE 'REGISTRY' ENTERED AT 17:35:17 ON 01 NOV 2007
L1              STRUCTURE UPLOADED
L2            0 S L1
L3           22 S L1 FUL

     FILE 'ZCAPLUS' ENTERED AT 17:36:30 ON 01 NOV 2007
L4           10 S L3

=> d l4 1- ibib abs hitstr
YOU HAVE REQUESTED DATA FROM 10 ANSWERS - CONTINUE? Y/(N):y

L4   ANSWER 1 OF 10  ZCAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         2006:1041179  ZCAPLUS
DOCUMENT NUMBER:          145:419471
TITLE:                    Preparation of peptide 1,2-ethylenediamine derivatives
                          for the treatment of Alzheimer's disease
INVENTOR(S):              Eickmeier, Christian; Fuchs, Klaus; Peters, Stefan;
                          Dorner-Ciossek, Cornelia; Heine, Niklas; Handschuh,
                          Sandra; Klinder, Klaus; Kostka, Marcus
PATENT ASSIGNEE(S):       Boehringer Ingelheim International GmbH, Germany;
                          Boehringer Ingelheim Pharma Gmbh & Co. KG
SOURCE:                   PCT Int. Appl., 325pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     ---------------      ----   --------    --------------------     --------
     WO 2006103038         A1    20061005    WO 2006-EP2769           20060327
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
```

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

US 2006223759 A1 20061005 US 2006-278059 20060330
PRIORITY APPLN. INFO.: EP 2005-6939 A 20050330
OTHER SOURCE(S): MARPAT 145:419471

GI



I



II

AB The invention relates to substituted 1,2-ethylenediamines I [A is aryl or heteroaryl which may be substituted; B is C1-4-alkylene or oxyalkylene; R1, R2, R5-R9 are H, (un)substituted alkyl, (hetero)aryl, etc. (but R2 is not H); R3, R4 are H, alkyl, F, CF3, CHF2, CH2F; X1-X4 are N, C or substituted carbon (0-3 of these groups are N)], including tautomers, diastereomers, enantiomers, and salts, and their use in the treatment of Alzheimer's disease (AD) and similar diseases. Thus, peptide II was prepared by a multistep sequence using reactants which include di-Me 5-aminoisophthalate, (R)-1-phenylethylamine, and protected amino acids. Compds. of the invention listed in a table have IC50 values < 30 μM in the β-secretase inhibition assay.

IT 911792-28-4P 911792-31-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of peptide ethylenediamine derivs. for treatment of Alzheimer's disease)

RN 911792-28-4 ZCAPLUS

CN L-Valinamide, N-[(2S)-2-[[[2'-cyano-5-[[[(1R)-1-phenylethyl]amino]carbonyl][1,1'-biphenyl]-3-yl]carbonyl]amino]-3-(4-nitrophenyl)propyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 911792-31-9 ZCAPLUS
CN L-Valinamide, N-[(2S)-3-(4-aminophenyl)-2-[[[2'-cyano-5-[[[(1R)-1-phenylethyl]amino]carbonyl][1,1'-biphenyl]-3-yl]carbonyl]amino]propyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 10 ZCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:	2005:141021 ZCAPLUS
DOCUMENT NUMBER:	142:261788
TITLE:	Preparation of aryl and heteroaryl amino acid derivatives as antagonists of factor IX and/or factor XI
INVENTOR(S):	Mjalli, Adnan M. M.; Andrews, Robert C.; Guo, Xiao-Chuan; Christen, Daniel Peter; Gohimmukkula, Devi Reddy; Huang, Guoxiang; Rothlein, Robert; Tyagi, Sameer; Yaramasu, Tripura; Behme, Christopher
PATENT ASSIGNEE(S):	Transtech Pharma, Inc., USA
SOURCE:	PCT Int. Appl., 313 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005014533	A2	20050217	WO 2004-US25463	20040806
WO 2005014533	A3	20050407		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004263508	A1	20050217	AU 2004-263508	20040806
CA 2531796	A1	20050217	CA 2004-2531796	20040806
US 2005049310	A1	20050303	US 2004-913882	20040806
US 2005059713	A1	20050317	US 2004-913216	20040806
EP 1660439	A2	20060531	EP 2004-780318	20040806
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1832920	A	20060913	CN 2004-80022750	20040806
JP 2007501844	T	20070201	JP 2006-523245	20040806
PRIORITY APPLN. INFO.:			US 2003-493878P P	20030808
			US 2003-493879P P	20030808
			US 2003-493903P P	20030808
			WO 2004-US25463 W	20040806

OTHER SOURCE(S): MARPAT 142:261788

AB The invention relates to aryl and heteroaryl compds. Ar2-K [Ar2 is (un)substituted aryl, heteroaryl, fused cycloalkylaryl, fused cycloalkylheteroaryl, fused heterocyclylaryl or fused heterocyclylheteroaryl; K is a carbamoyl group of defined structure or Ar1-V-CH[(CH2)0-2-G]-X-, where G is H, CO2R1, CH2OR1, COR1, CR1:NOR2, CONR1R2, CONHNH2 or an acid or ester isostere and R1, R2 independently are H, alkyl, alkoxy, aryl, alkylaminoacyl, etc. or may combine to form a ring; V is (CH2)1-2-S-(CH2)0-2, (CH2)1-2-S, S-(CH2)0-2 (or corresponding sulfonyl derivs.), (CH2)1-2-O-(CH2)0-2, (CH2)1-2-NR7-(CH2)0-2, (CH2)1-2-O or a direct bond, where R7 is H, alkyl, aryl, etc. (the CH2 or CH2CH2 groups may be substituted); X is NR8, CONR8, NR8CO, NR8CONR9, O2CNR8, SO2NR8 or NR8SO2NR9, where R8, R9 are independently H, alkyl, aryl, etc.; Ar1 is a group as defined for Ar2] and their pharmaceutical compns. Compds. Ar2-K may be antagonists or partial antagonist of factor IX and/or factor XI and thus may be useful for inhibiting the intrinsic pathway of blood coagulation. Applications include the management, treatment and/or control of diseases caused in part by the intrinsic clotting pathway. Thus, (25)-[5-bromo-2-(4-trifluoromethylbenzyloxy)benzoylamino]-3-(2'-phenoxybiphenyl-4-yl)propionic acid, prepared by amidation and O-benzylation reactions, inhibited factor IX or factor XI in the in vitro clotting assay with IC50 < 30 micromolar.

IT 660826-69-7P 660826-70-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aryl and heteroaryl amino acid derivs. as antagonists of factor IX and/or factor XI)

RN 660826-69-7 ZCAPLUS

CN L-Phenylalanine, 4-(3-thienyl)-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 660826-70-0 ZCAPLUS
CN L-Phenylalanine, 4-(3-thienyl)-N-[[4'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 3 OF 10 ZCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:696336 ZCAPLUS
DOCUMENT NUMBER: 141:207231
TITLE: Preparation of N-phenethylpiperidine-1-carboxamide, N-phenethylbenzamides, and N-phenethylbiphenyl-4-carboxamide derivatives as melanin-concentrating hormone antagonists
INVENTOR(S): Ishihara, Yuji; Kamata, Makoto; Takekawa, Shiro
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 227 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004072018	A1	20040826	WO 2004-JP1467	20040212

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

JP 2004262931	A	20040924	JP 2004-34598		20040212
EP 1593667	A1	20051109	EP 2004-710515		20040212
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
US 2006128690	A1	20060615	US 2005-545120		20050810
PRIORITY APPLN. INFO.:			JP 2003-34010	A	20030212
			WO 2004-JP1467	W	20040212

OTHER SOURCE(S): MARPAT 141:207231
GI



I

AB Amine compds. represented by the formula (I) or salts thereof [Ar1 = (un)substituted cyclic group; R = H, C1-6 alkyl, halo-C1-6 alkyl, each (un)substituted Ph or pyridyl; Ra1-Ra4 = H, C1-6 alkyl, halo-C1-6 alkyl, halo, cyano, C1-6 alkoxy-, halo-C1-6 alkoxy, C1-6 alkylthio, halo-C1-6 alkylthio, NH2, mono- or di(C1-6 alkyl)amino, CHO, C1-6 alkylcarbonyl, halo-C1-6 alkylcarbonyl, C1-6 alkylsulfonyl, halo-C1-6 alkylsulfonyl, each (un)substituted pyridyl or Ph; Ar = (un)substituted mono cyclic aromatic ring; Y = alkylene or haloalkylene; R1 , R2 = H, C1-6 alkyl; or NR1R2 together forms (un)substituted N-containing heterocyclic ring; or NR1 and Y together forms (un)substituted N-containing heterocyclic ring and R2 = H or C1-6 alkyl; provided that when NR1R2 together forms N- containing heterocyclic ring or R = C1-4 alkyl, Ar1 = (un)substituted cyclic group] are prepared These compds. have antagonistic activity against melanin-concentrating hormone (MCH) and are useful as preventives/therapeutic agents for obesity, depression, or anxiety, or as antifeeding agents (appetite depressants). For example, N-[2-[4-[1-(1-azepanyl)ethyl]phenyl]ethyl]-4'-chloro-1,1'-biphenyl-4-carboxamide showed IC50 of 3 nM for inhibiting the binding of [36S]-guanosine 5'-(γ-thio)triphosphate to CHO cells expressing human SLC-1 receptor (MCH1). A tablet formulation containing 4'-chloro-N-[2-[4-(1-pyrrolidinylmethyl)phenyl]propyl]-1,1'-biphenyl-4-carboxamide was prepared

IT 742084-76-0P 742084-78-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-phenethylpiperidine-1-carboxamide, N-phenethylbenzamides, and N-phenethylbiphenyl-4-carboxamide derivs. as melanin-concentrating hormone antagonists)

RN 742084-76-0 ZCAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-chloro-N-[2-[4-(1-methyl-2-pyrrolidinyl)phenyl]ethyl]- (CA INDEX NAME)



RN 742084-78-2 ZCAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-methoxy-N-[2-[4-(1-methyl-2-pyrrolidinyl)phenyl]ethyl]- (CA INDEX NAME)



L4 ANSWER 4 OF 10 ZCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:143094 ZCAPLUS
DOCUMENT NUMBER: 140:199743
TITLE: Preparation of substituted (2S)-(arylamino)-3-(biphenyl-4-yl)propionic acids as antagonists of factor IX for inhibiting the intrinsic pathway of blood coagulation
INVENTOR(S): Mjalli, Adnan M. M.; Andrews, Robert C.; Guo, Xiao-chuan; Christen, Daniel Peter; Gohimmukkula, Devi Reddy; Huang, Guoxiang; Rothlein, Robert; Tyagi, Sameer; Yaramasu, Tripura; Behme, Christopher
PATENT ASSIGNEE(S): Transtech Pharma, Inc., USA
SOURCE: PCT Int. Appl., 326 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004014844	A2	20040219	WO 2003-US25045	20030808
WO 2004014844	A3	20050428		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2493008	A1	20040219	CA 2003-2493008	20030808

AU 2003265398	A1	20040225	AU 2003-265398		20030808
US 2004110832	A1	20040610	US 2003-637900		20030808
US 7122580	B2	20061017			
EP 1546089	A2	20050629	EP 2003-785150		20030808
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
JP 2005535710	T	20051124	JP 2004-527986		20030808
CN 1703395	A	20051130	CN 2003-819267		20030808
US 2006276518	A1	20061207	US 2006-500225		20060807
PRIORITY APPLN. INFO.:			US 2002-402272P	P	20020809
			US 2003-637900	A3	20030808
			WO 2003-US25045	W	20030808

OTHER SOURCE(S): MARPAT 140:199743

AB The title compds. Ar2XCH(VAr1)(CH2)cG [I; c = 0-2; G = H, CO2R1, CH2OR1, COR1, CR1:NOR2, an acid isostere (wherein R1, R2 = H, alkyl, aryl, etc.); V = (CH2)bO(CH2)a, (CH2)bNR7(CH2)a, (CH2)bO, (CH2)bNR7, (CH2)a, a bond (a = 0-2; b = 1-2; R7 = H, alkyl, aryl, etc.); X = NR8, COR8, NR8CO, etc. (R8 = H, alkyl, aryl, etc.); Ar1 = (un)substituted aryl, heteroaryl, cycloalkylaryl, etc.; Ar2 = (un)substituted aryl or heteroaryl], useful as antagonists, or more preferably, partial antagonists of factor IX and thus, may be used to inhibit the intrinsic pathway of blood coagulation, were prepared Thus, reacting Me 2-L-amino-3-biphenyl-4-yl-propionate with isoquinoline-3-carboxylic acid followed by hydrolysis afforded 81% 3-biphenyl-4-yl-(2S)-[(isoquinoline-3-carbonyl)amino]propionic acid. The compds. I inhibit factor IX with IC50 of less than 30 μM, and are useful in a variety of applications including the management, treatment and/or control of diseases caused in part by the intrinsic clotting pathway utilizing factor IX. Such diseases or disease states include stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures, long periods of confinement, and acquired or inherited pro-coagulant states. The pharmaceutical composition comprising the compound I is claimed.

IT 660826-45-9P 660826-69-7P 660826-70-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted (2S)-(arylamino)-3-(biphenyl-4-yl)propionic acids as antagonists of factor IX for inhibiting intrinsic pathway of blood coagulation)

RN 660826-45-9 ZCAPLUS

CN L-Phenylalanine, 4-(4-pyridinyl)-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



10/ 647,156

RN 660826-69-7 ZCAPLUS
CN L-Phenylalanine, 4-(3-thienyl)-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 660826-70-0 ZCAPLUS
CN L-Phenylalanine, 4-(3-thienyl)-N-[[4'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 5 OF 10 ZCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:319711 ZCAPLUS
DOCUMENT NUMBER: 138:338153
TITLE: Preparation of 2'-methyl-5'-(1,3,4-oxadiazol-2-yl)-1,1'-biphenyl-4-carboxamides as p38 kinase inhibitors
INVENTOR(S): Angell, Richard Martyn; Bamborough, Paul; Cockerill, George Stuart; Walker, Ann Louise
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 61 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2003032986	A1	20030424	WO 2002-EP11569	20021016
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002338895	A1	20030428	AU 2002-338895	20021016
EP 1435949	A1	20040714	EP 2002-777313	20021016
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005507910	T	20050324	JP 2003-535789	20021016
US 2004266839	A1	20041230	US 2004-492713	20040415
PRIORITY APPLN. INFO.:			GB 2001-24936	A 20011017
			WO 2002-EP11569	W 20021016

OTHER SOURCE(S): MARPAT 138:338153
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; R1 = (un)substituted Ph; R2 = H, alkyl, (CH2)pcycloalkyl; R3 = II (wherein R4 = H, alkyl); U = Me, halo; X, Y = H, Me, halo; m = 0-4; n = 0-2; p = 0-2], useful as pharmaceuticals, particularly as p38 kinase inhibitors, were prepared E.g., 6-step synthesis of the carboxamide III, starting from 3-bromo-4-methylbenzoic acid, was given.

IT 515153-24-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2'-methyl-5'-(1,3,4-oxadiazol-2-yl)-1,1'-biphenyl-4-carboxamides as p38 kinase inhibitors)

RN 515153-24-9 ZCAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, 2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)-N-[2-[4-[(methylsulfonyl)amino]phenyl]ethyl]- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 10 ZCAPLUS COPYRIGHT 2007 ACS on STN

10/ 647,156

ACCESSION NUMBER: 2003:87650 ZCAPLUS
DOCUMENT NUMBER: 138:397876
TITLE: Unusual Fluorescent Properties of N-(9-Anthroyl) Derivatives of Aromatic Amines
AUTHOR(S): Molotkovsky, Jul. G.
CORPORATE SOURCE: Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, 117997, Russia
SOURCE: Russian Journal of Bioorganic Chemistry (Translation of Bioorganicheskaya Khimiya) (2003), 29(1), 94-95
CODEN: RJBCET; ISSN: 1068-1620
PUBLISHER: MAIK Nauka/Interperiodica Publishing
DOCUMENT TYPE: Journal
LANGUAGE: English

AB 9-Anthroyl derivs. of some aromatic amines exhibit unusual fluorescence characteristics. In solvents of low and medium polarity (hexane, chloroform, DMF, and tert-butanol), their emission maxima are shifted to longer wavelengths as compared to the spectra recorded in polar solvents (ethanol and methanol); the red shift is accompanied by an increase in the fluorescence quantum yield. Possible reasons of such an anomalous spectral shift are discussed.

IT 529484-27-3
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(unusual fluorescent properties of N-(9-anthroyl) derivs. of aromatic amines)

RN 529484-27-3 ZCAPLUS
CN Butanoic acid, [1,1'-biphenyl]-4,4'-diylbis[carbonylimino[(1S,2R)-1-[4-[(9-anthracenylcarbonyl)amino]phenyl]-2,1,3-propanetriyl]] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 10 ZCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1998:543220 ZCAPLUS
DOCUMENT NUMBER: 129:175563
TITLE: 4-Substituted quinoline derivatives and 4-substituted quinoline combinatorial libraries
INVENTOR(S): Hayes, Thomas K.; Forood, Behrouz; Kiely, John S.
PATENT ASSIGNEE(S): Trega Biosciences, Inc., USA
SOURCE: PCT Int. Appl., 124 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9834115	A1	19980806	WO 1997-US22391	19971205

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,

GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

CA 2279977	A1	19980806	CA 1997-2279977	19971205
AU 9881919	A	19980825	AU 1998-81919	19971205
EP 977989	A1	20000209	EP 1997-949775	19971205
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
US 6262269	B1	20010717	US 1998-17785	19980203
US 6388081	B1	20020514	US 1999-376670	19990816

PRIORITY APPLN. INFO.: US 1997-795392 A 19970204
US 1997-126414P P 19970204
WO 1997-US22391 W 19971205
US 1998-17785 A3 19980203

OTHER SOURCE(S): MARPAT 129:175563

GI



I



II

AB The invention relates to novel 4-substituted quinoline derivs. I, their salts, and combinatorial libraries containing mixts. of two or more such compds. [wherein R1 = bond, (un)substituted alk(en/yn)ylene, cycloalk(en)ylene, phenylene, naphthylene, heterocycle, heteroaryl, amino, CH2CONH, (CH2)pAr(CH2)q, etc.; p, q = 0-6 but both cannot be 0; Ar = (un)substituted Ph or heteroaryl; R2, R3, R4 = H, halo, (un)protected OH, cyano, NO2, (un)substituted alk(en/yn)yl, alkoxy, cycloalk(en)yl, heterocyclyl, phenylalkyl, Ph, naphthyl, etc.; R5 = H, (un)substituted alk(en/yn)yl, cycloalk(en)yl, Ph, naphthyl, phenylalkyl, (un)protected CO2H, acyl, heterocyclyl, etc.; R6 = H, (un)substituted Ph, naphthyl, 2-oxopyrrolidin-1-yl and higher homologs, (un)substituted NHCHO; R7 = H, (un)substituted alkyl; Y = CO2H, OH, SH, NHR8, CONHR8, CH2OH, CH2NH2, CH2NHR8; R8 = H, (un)substituted alkyl, or functionalized resin; R9 = H, (un)substituted alkyl, phenylalkyl, acyl, PhSO2, alkylsulfonyl, alkylaminocarbonyl, or PhNHCO, or is absent; dotted lines = optional pi bonds]. The invention also relates to the generation of such libraries. In 12 examples, libraries of I ranging in size from 2380 to 39,440 compds. were prepared as mixed sublibraries. Data for control compds. (samples of individually known intermediates and products, cleaved from simultaneously processed control resins) are given for some examples. Both quinoline and tetrahydroquinoline libraries were prepared For instance, tea-bags of MBHA resin were each coupled with L- or D-N-BOC-p-nitrophenylalanine, the BOC groups were removed from both, and the amino groups were each acylated with 170 carboxylic acids. The acylated, resin-bound products were mixed and reduced at the nitro group, and the amine product mixts. were condensed with 58 different aldehydes and cyclized with 4-methoxystyrene. Cleavage of the resin-bound products with HF gave mixed sublibraries of I. Individual control samples of products, such as II [R5 = 1-naphthyl,

2,3-difluorophenyl, cyclohexyl, etc.], were obtained by reactions of pure, resin-bound L-N-propanoyl-p-aminophenylalanine control samples with individual aldehydes and 4-methoxystyrene. Potential applications of I (no data) may include use as antibacterials, NMDA antagonists, or analgesics.

IT 211377-24-1P 211377-28-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(resin-cleavage control intermediate; preparation of tricyclic tetrahydroquinoline derivs. and combinatorial libraries)

RN 211377-24-1 ZCAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[2-amino-1-[(4-nitrophenyl)methyl]-2-oxoethyl]-4'-ethyl- (9CI) (CA INDEX NAME)



RN 211377-28-5 ZCAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[2-amino-1-[(4-nitrophenyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 10 ZCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1998:543216 ZCAPLUS
DOCUMENT NUMBER: 129:175562
TITLE: Tricyclic tetrahydroquinoline derivatives and tricyclic tetrahydroquinoline combinatorial libraries
INVENTOR(S): Hayes, Thomas K.; Kiely, John S.
PATENT ASSIGNEE(S): Trega Biosciences, Inc., USA
SOURCE: PCT Int. Appl., 119 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9834111	A1	19980806	WO 1997-US22206	19971205

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,

GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

US 5925527	A	19990720	US 1997-795893		19970204
CA 2279980	A1	19980806	CA 1997-2279980		19971205
AU 9855928	A	19980825	AU 1998-55928		19971205
NZ 337046	A	20000128	NZ 1997-337046		19971205
EP 983507	A1	20000308	EP 1997-952280		19971205

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI

PRIORITY APPLN. INFO.: US 1997-795893 A 19970204
WO 1997-US22206 W 19971205

OTHER SOURCE(S): MARPAT 129:175562

GI



I II

AB The invention relates to novel tricyclic tetrahydroquinoline compds. I, their salts, and combinatorial libraries containing mixts. of two or more such compds. [wherein R1 = bond, (un)substituted alk(en/yn)ylene, cycloalk(en)ylene, phenylene, naphthylene, heterocycle, heteroaryl, amino, CH2CONH, (CH2)pAr(CH2)q; p, q = 0-6 but both cannot be 0; Ar = (un)substituted Ph or heteroaryl; R2, R3, R4 = H, halo, (un)protected OH, cyano, NO2, (un)substituted alk(en/yn)yl, alkoxy, cycloalk(en)yl, heterocyclyl, phenylalkyl, Ph, naphthyl, etc.; R5 = H, (un)substituted alk(en/yn)yl, cycloalk(en)yl, Ph, naphthyl, phenylalkyl, (un)protected CO2H, acyl, heterocyclyl, etc.; R6 = H, (un)substituted alkyl, phenylalkyl, acyl, PhSO2, alkylsulfonyl, alkylaminocarbonyl, PhNHCO; n = 1-3; Y = CO2H, OH, SH, NHR7, CONHR7, CH2OH, CH2NH2, CH2NHR7; R7 = H, (un)substituted alkyl, or functionalized resin; R1 must be present and R5 ≠ Ph when Y = CO2H]. The invention also relates to the generation of such libraries. In 2 examples, libraries of 2774 and approx. 17,000 compds. I were prepared as mixed sublibraries. Data for control compds. (samples of individually known intermediates and products, cleaved from simultaneously processed control resins) are given. For instance, tea-bags of MBHA resin were each coupled with one of 19 aminobenzoic acids, such as 4-aminobenzoic acid. Diagnostic cleavage of each of these resins with HF gave 19 aminobenzamide controls in 34-99% yield. The 19 resins were mixed together and placed in new tea-bags, then condensed with 73 different aldehydes, and finally cyclized with cyclopentadiene. Cleavage of the resin-bound products with HF gave approx. 73 mixts. of 38 compds. (counting sep. enantiomers). Individual control samples of products, such as II [R5 = H, CH2Cl, cyclohexyl, CO2H, (un)substituted Ph, etc.], were typically obtained in 50-100% yield by reactions of pure, resin-bound 4-aminobenzoic acid control samples in sibling tea-bags. Potential applications of I (no data) may include use as antibacterials or analgesics.

IT 211377-24-1P 211377-28-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(resin-cleavage control intermediate; preparation of tricyclic tetrahydroquinoline derivs. and combinatorial libraries)

RN 211377-24-1 ZCAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, N-[2-amino-1-[(4-nitrophenyl)methyl]-2-

oxoethyl]-4'-ethyl- (9CI) (CA INDEX NAME)



RN 211377-28-5 ZCAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[2-amino-1-[(4-nitrophenyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 10 ZCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1995:480169 ZCAPLUS
DOCUMENT NUMBER: 122:240447
TITLE: Preparation of peptideamide analogs as tachykinin antagonists.
INVENTOR(S): Pieper, Helmut; Austel, Volkhard; Jung, Birgit; Buerger, Erich; Entzeroth, Michael
PATENT ASSIGNEE(S): Karl Thomas GmbH, Germany
SOURCE: Ger. Offen., 101 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4243858	A1	19940630	DE 1992-4243858	19921223
PRIORITY APPLN. INFO.:			DE 1992-4243858	19921223

OTHER SOURCE(S): MARPAT 122:240447
GI



I

AB R4R5NACONHCHR3CXNR1R2 [A = 1,2-cyclopentylene, CHR6; R6 = H, (substituted) alkyl, Ph; R1 = H, (Ph- or pyridyl-substituted) alkyl; R2 = H, (amino- or guanidino-substituted) Ph, pyridyl, (cyclohexyl-, Ph-, or pyridyl-substituted) alkyl, etc.; R1R2N = (substituted) piperazinyl; R3 = H, (phenyl)alkyl, guanidino- or amino-substituted alkyl, aminocarbonylalkyl, etc.; R4 = H, (phenyl)alkyl; R5 = protecting group, (substituted) alkyl, alkanoyl, alkoxycarbonyl, alkylaminocarbonyl, PhCO, naphthylcarbonyl, biphenylcarbonyl, PhSO2, etc.; X = (H, H), O, S; the C atom bearing the R3 substituent is L; the C atom bearing the R6 substituent is D or L], were prepared Thus, title compound I (prepared by solution phase methods) showed IC50 = 2 nM for neurokinin-1 receptor binding with IM-9 cells. Tablets were prepared containing I.

IT 162175-54-4P 162175-55-5P 162177-15-3P
162177-16-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as tachykinin antagonist)

RN 162175-54-4 ZCAPLUS

CN Carbamic acid, [5-[[3-(4-amino-3,5-dibromophenyl)-2-[([1,1'-biphenyl]-4-ylcarbonyl)amino]-1-oxopropyl]amino]-6-[4-(2-hydroxyphenyl)-1-piperazinyl]-6-oxohexyl]-, phenylmethyl ester, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 162175-55-5 ZCAPLUS

CN Benzenepropanamide, 4-amino-N-[5-amino-1-[[4-(2-hydroxyphenyl)-1-piperazinyl]carbonyl]pentyl]-α-[([1,1'-biphenyl]-4-ylcarbonyl)amino]-3,5-dibromo-, dihydrobromide, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HBr

RN 162177-15-3 ZCAPLUS
CN L-Lysinamide, 4-amino-N-([1,1'-biphenyl]-4-ylcarbonyl)-3,5-dibromo-D-phenylalanyl-N-methyl-N-(2-phenylethyl)-N6-[(phenylmethoxy)carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 162177-16-4 ZCAPLUS
CN L-Lysinamide, 4-amino-N-([1,1'-biphenyl]-4-ylcarbonyl)-3,5-dibromo-D-phenylalanyl-N-methyl-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 10 OF 10 ZCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1984:491715 ZCAPLUS
DOCUMENT NUMBER: 101:91715
TITLE: Bis(aminoneopentyl) aromatics and polyamides derived from them
INVENTOR(S): Frazer, August H.; Harris, John F., Jr.
PATENT ASSIGNEE(S): du Pont de Nemours, E. I., and Co. , USA
SOURCE: U.S., 21 pp. Division of U.S. Ser. No. 266,058.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4451642	A	19840529	US 1982-420511	19820920
US 4564705	A	19860114	US 1981-266058	19810521
PRIORITY APPLN. INFO.:			US 1977-804853 A2	19770608
			US 1981-266058 A3	19810521

OTHER SOURCE(S): CASREACT 101:91715; MARPAT 101:91715

AB Aromatic-aliphatic diamines having formula (H2NCH2CMe2CH2)2Z (Z = arylene or substituted arylene) are prepared and used for the preparation of thermally stable rigid polyamides. Thus, 8.50 g 4,4'-bis(bromomethyl)biphenyl [20248-86-6] was added to a mixture of THF 250, (iso-Pr)2NH [108-18-9] 7.00, and 2.4 M BuLi 21.0 mL and 3.42 g Me2CHCN in 20 mL THF. The mixture was stirred at -76° to give 6.8 g 4,4'-bis(2-methyl-2-cyanopropyl)biphenyl (I) [69774-40-9]. A mixture of 6.54 g I in 400 mL PhMe and 71 mL 25% (iso-Bu)2AlH in PhMe was refluxed for 17 h and 40 min. A solution of 5 mL water in 22 mL MeOH was added dropwise followed by another dropwise addition of a solution of 20 mL water in 40 mL MeOH to give 4,4'-bis(2,2-dimethyl-3-aminopropyl)biphenyl (II) [69761-38-2]. A mixture of 9.6500 g II and 9.4659 g di-Ph terephthalate (III) was heated from 210° to 300° for 6 h and 44 min to give a copolymer [91629-01-5]. The weight loss of this copolymer after heating at 375° for 1 h was 17.5%, compared with 26.5% for 4,4'-bis(1,1-dimethyl-3-aminopropyl)biphenyl-III copolymer.

IT 91629-08-2P
RL: PREP (Preparation)
(manufacture of heat-stable)

RN 91629-08-2 ZCAPLUS
CN Poly[iminocarbonyl[1,1'-biphenyl]-4,4'-diylcarbonylimino(2,2-dimethyl-1,3-